Abstract
Intercountry differences in adverse drug reaction (ADR) reporting to the World Health Organization (WHO), from within the European Community (EC), will gain more significance as the Community develops its pharmacovigilance strategies. At the moment little is known about the extent or causes of differences. Differences in the medical traditions of reporting, practical issues in data transfer, differences in drug utilization, and regional publicity of ADR problems are just some of the reasons for apparent differences in incidence of adverse drug reaction reports. The WHO database is useful in showing differences among countries, and the availability of drug utilization data will allow for a start in a more meaningful analysis of such differences.
Get full access to this article
View all access options for this article.